This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.

Inclusion Criteria:

• No systemic disease as determined by a physical examination, clinical laboratory evaluation, and an ECG
• Schirmer's I Test ≥ 10mm/5 minutes with anesthesia
• Corrected Snellen acuity of 20/40 or better in both eyes

Exclusion Criteria:

• Subjects diagnosed with any ocular disease other than refraction error
• Subjects with intraocular pressure >21 mmHg
• Use of a contact lens within 7 days prior to administration of the first dose
• Subjects with history of ocular surgery
• Subjects with a history of laser refractive surgery